NCT04874350Phase 2Completed

A Study to Assess the Efficacy, Safety, and Tolerability of Oral LPCN 1148 in Male Subjects With Cirrhosis of the Liver and Sarcopenia

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2023-12-18Actual

Enrollment · participants30Actual

Source updated2024-03-15Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Liver Cirrhosis; Sarcopenia

Treatments or interventions studied

LPCN 1148Drug
PlaceboDrug

Primary outcomes · main study measures

measure: Change from baseline in Skeletal Muscle Index in LPCN 1148 treated subjects compared to placebo; timeFrame: 24 weeks

History coverage

Imported research includes version dates later than the current official API record (2024-03-15). Disputed observations are retained for audit and excluded from trusted change feeds and sponsor statistics. Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history